Technical Analysis for NOVN - Novan, Inc.

Grade Last Price % Change Price Change
F 8.03 -3.37% -0.28
NOVN closed down 3.37 percent on Tuesday, July 27, 2021, on 11 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Aug 12
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical NOVN trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
BB Squeeze Started Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Down 3 Days in a Row Weakness -3.37%
Narrow Range Bar Range Contraction -4.40%
Wide Bands Range Expansion -4.40%
Older End-of-Day Signals for NOVN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 8 hours ago
Down 3% about 8 hours ago
Down 2 % about 9 hours ago
Down 1% about 9 hours ago
Fell Below Previous Day's Low about 9 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Novan, Inc. Description

Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.


Sector: Healthcare
Industry: Biotechnology
Keywords: Infectious Diseases Organ Systems Stage Pharmaceutical Dermatology Acne Chemical Entities Skin Diseases Fungal Infection Acne Vulgaris Fungal Infections Cutaneous Conditions Genital Wart Inflammatory Skin Diseases Late Stage Pharmaceutical Treatment Of Inflammatory Skin Diseases

Is NOVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 25.9
52 Week Low 3.011
Average Volume 4,798,579
200-Day Moving Average 10.70
50-Day Moving Average 10.03
20-Day Moving Average 8.95
10-Day Moving Average 8.43
Average True Range 0.77
ADX 11.61
+DI 24.65
-DI 27.47
Chandelier Exit (Long, 3 ATRs) 8.62
Chandelier Exit (Short, 3 ATRs) 10.19
Upper Bollinger Bands 10.21
Lower Bollinger Band 7.68
Percent B (%b) 0.14
BandWidth 28.32
MACD Line -0.60
MACD Signal Line -0.59
MACD Histogram -0.0111
Fundamentals Value
Market Cap 1.1 Billion
Num Shares 137 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -8.37
Price-to-Sales 6.33
Price-to-Book 10.61
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.60
Resistance 3 (R3) 8.61 8.43 8.51
Resistance 2 (R2) 8.43 8.28 8.43 8.47
Resistance 1 (R1) 8.23 8.20 8.14 8.22 8.44
Pivot Point 8.05 8.05 8.01 8.05 8.05
Support 1 (S1) 7.85 7.90 7.76 7.84 7.62
Support 2 (S2) 7.67 7.82 7.67 7.59
Support 3 (S3) 7.47 7.67 7.56
Support 4 (S4) 7.46